Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multi-center, Open-label Study of the Safety and Efficacy of a Stepwise Dose-escalation Schedule of Lenalidomide Monotherapy in Subjects With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia

NCT00419250 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT00419250
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00419250 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multi-center, Open-label Study of the Safety and Efficacy of a Stepwise Dose-escalation Schedule of Lenalidomide Monotherapy in Subjects With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia
Lead sponsor
Celgene
Phase
Phase 1
Overall status
Completed
Start date
December 1, 2006
Completion date
June 1, 2010
Enrollment
52 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, leukemia, b-cell, chronic